CYT Cyteir Therapeutics Inc.

19.25
+1.11  (+6%)
Previous Close 18.14
Open 17.83
52 Week Low 14
52 Week High 23.1
Market Cap $663,481,704
Shares 34,466,582
Float 22,629,042
Enterprise Value $579,286,703
Volume 178,029
Av. Daily Volume 120,776
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
CYT-0851 - combo
Solid tumors
Phase 1
Phase 1
Phase 1 combination trial to commence 2H 2021.
CYT-0851
Solid tumors
Phase 1/2
Phase 1/2
Phase 2 trial to be initiated 2H 2021.

Latest News

  1. Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional 1,110,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Cyteir's common stock is listed on The Nasdaq Global Select Market under the ticker symbol "CYT."

    The gross proceeds to Cyteir from the offering were $133.2 million…

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional 1,110,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Cyteir's common stock is listed on The Nasdaq Global Select Market under the ticker symbol "CYT."

    The gross proceeds to Cyteir from the offering were $133.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

    J.P. Morgan, Morgan Stanley and BofA Securities acted as joint book-running managers for the offering and Wedbush PacGrow acted as co-manager.

    A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on June 17, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at ; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by telephone: 1-866-718-1649; or BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at: .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Cyteir Therapeutics, Inc.

    Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir's wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

    Forward-Looking Statements

    This press release contains "forward-looking statements" regarding Cyteir's plans for its proposed initial public offering. Forward-looking statements include statements regarding the proposed public offering and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors set forth under the heading "Risk Factors" in Cyteir's registration statement on Form S-1. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

    For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

    View Full Article Hide Full Article
  2. Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional 1,110,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. The shares are scheduled to begin trading on The Nasdaq Global Select Market on June 18, 2021 under the ticker symbol "CYT."

    The gross proceeds of the offering, before…

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional 1,110,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. The shares are scheduled to begin trading on The Nasdaq Global Select Market on June 18, 2021 under the ticker symbol "CYT."

    The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cyteir, are expected to be approximately $133 million excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on June 22, 2021, subject to the satisfaction of customary closing conditions.

    J.P. Morgan, Morgan Stanley and BofA Securities are acting as joint book-running managers for the offering and Wedbush PacGrow is acting as co-manager.

    A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 17, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at ; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by telephone: 1-866-718-1649; or BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at: .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Cyteir Therapeutics, Inc.

    Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir's wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

    Forward-Looking Statements

    This press release contains "forward-looking statements" regarding Cyteir's plans for its proposed initial public offering. Forward-looking statements include statements regarding the proposed public offering and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding when Cyteir can complete the offering and other factors set forth under the heading "Risk Factors" in Cyteir's registration statement on Form S-1. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

    For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

    View Full Article Hide Full Article
View All Cyteir Therapeutics Inc. News